Hagop M. Kantarjian
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency

Dr. Hagop M. Kantarjian

Oncology | Hematology
1515 Holcombe Blvd, 
Houston, TX 
 (827.9 mi)
Clinical Trials:Currently Recruiting for 2 Trials
43 Years of Experience
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
1515 Holcombe Blvd, 
Houston, TX 
 (827.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Hagop Kantarjian is an Oncologist and a Hematologist in Houston, Texas. Dr. Kantarjian has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 1425 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

MD Anderson
1515 Holcombe Blvd, Houston, TX 77030
Other Locations
MD Anderson
2130 W Holcombe Blvd, Life Sciences Plaza, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Recruiting
Publish Date: January 27, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Inotuzumab, 6-Mercaptopurine, Methotrexate, Prednisone, Rituximab, Vincristine
Study Phase: Phase 1/Phase 2
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Recruiting
Publish Date: December 10, 2024
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Cytarabine, Methotrexate, Ponatinib
Study Phase: Phase 2
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drugs: Asciminib Add-On, Imatinib, Nilotinib
Study Phase: Phase 2
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
Study Phase: Phase 2
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Ponatinib, Prednisone, Rituximab, Vincristine
Study Phase: Phase 2
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drugs: Dasatinib, Venetoclax
Study Phase: Phase 2
Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia
Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: June 02, 2022
Intervention Type: Procedure, Drug
Study Drug: Decitabine
Study Phase: Phase 2
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Carboplatin, Arsenic Trioxide
Study Phase: Phase 2
A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia
A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

1425 Total Publications

Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
Journal: Leukemia & lymphoma
Published: January 10, 2025
Similar Doctors
Elias J. Jabbour
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (0.6 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances

Elias Jabbour is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Jabbour and is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Partow Kebriaei
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Partow Kebriaei
Hematology Oncology | Hematology | Transplant Surgery
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Partow Kebriaei
Hematology Oncology | Hematology | Transplant Surgery

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (0.6 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances

Partow Kebriaei is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Kebriaei and is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Nitin B. Jain
Hematology | Oncology | Hematology Oncology
Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Nitin B. Jain
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (0.6 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances

Nitin Jain is a Hematologist and an Oncologist in Houston, Texas. Dr. Jain and is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Endoscopy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile